Floatz logo

Admilparant

Pulmonary Fibrosis

Bristol-Myers SquibbSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Pulmonary Fibrosis cohort.

Asset / SponsorPhaseRating
Acetylcysteine
Boehringer Ingelheim
Phase 3BB
Nintedanib
Boehringer Ingelheim
Phase 3BB
Pirfenidone
Boehringer Ingelheim
Phase 2BB
Sildenafil
Alicia Gerke
Phase 3BB
Interferon Gamma-1B
NYU Langone Health
Phase 3BB

View all 34 →

Same molecule, other indications

Admilparant is also rated in:

idiopathic pulmonary fibrosisActive
B
Indicative · Phase 3
59 / 100
View asset →
liver disorderActive
CC
Indicative · Phase 1
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →